MAPT and Alzheimer disease: As expected, we revealed significantly increased levels of Aβ peptide (Figure 1A,B) and of hyperphosphorylated Tau protein (P-Tau, Figure 1A,C) in AD brains while full-length βAPP (Figure 1A,E) remained unchanged.